Bictegravir (sodium)
Bictegravir sodium is a potent inhibitor of HIV-1 integrase, with an IC50 of 7.5 nM. Bictegravir sodium exhibits potent and selective anti-HIV activity and low cytotoxicity[1].
Product Specifications
CAS Number
[1807988-02-8]
Product Name Alternative
GS-9883 (sodium)
UNSPSC
12352005
Target
HIV; HIV Integrase
Type
Reference compound
Related Pathways
Anti-infection; Metabolic Enzyme/Protease
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/bictegravir-sodium.html
Purity
99.62
Solubility
DMSO : 16.67 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C1N([C@](CC2)([H])C[C@]2([H])O3)[C@@]3([H])CN(C=C(C(NCC(C(F)=CC(F)=C4)=C4F)=O)C5=O)C1=C5O[Na]
Molecular Formula
C21H17F3N3NaO5
Molecular Weight
471.36
References & Citations
[1]Tsiang M, et al. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile. Antimicrob Agents Chemother. 2016 Nov 21;60 (12) :7086-7097.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
HIV-1
Citation 01
Antiviral Res. 2025 Sep 11:106283.|Biomed Pharmacother. 2025 Nov 28:193:118831.|Antimicrob Agents Chemother. 2019 Dec 20;64 (1) :e01717-19.|bioRxiv. 2020 May.|Farmaceutická fakulta v Hradci Králové. 2020 Jun.|J Chromatogr B Analyt Technol Biomed Life Sci. 2025 Oct 1.|J Infect Dis. 2022 Nov 28;226 (11) :1992-2001.|J Infect Dis. 2025 Jul 15:jiaf362.|Open Forum Infect Dis. 2024 Nov 29;12 (1) :ofae705.|Pharmaceutics. 2022 Aug 24;14 (9) :1761.|Preprints. 2024 Apr 19.|Preprints. 2024 Apr 23.|Sci Adv. 2023 Jul 14;9 (28) :eadg2955.|Science. 2020 Feb 14;367 (6479) :806-810. |University of British Columbia. 2024 Apr 18.|Viruses. 2024 Oct 13;16 (10) :1607.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
